Black Rock Inc. Acorda Therapeutics Inc Transaction History

Black Rock Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.55 - $1.0 $79 - $145	-145 Reduced 0.11%	135,452 $79,000
Q4 2022 Feb 13, 2023	SELL	$0.52 - $0.77 $96 - $142	-185 Reduced 0.14%	135,597 $104,000
Q3 2022 Nov 14, 2022	SELL	$0.29 - $0.53 $1,084 - $1,982	-3,740 Reduced 2.68%	135,782 $40,000
Q2 2022 Aug 12, 2022	SELL	$0.3 - $1.67 $7,785 - $43,339	-25,952 Reduced 15.68%	139,522 $66,000
Q1 2022 May 12, 2022	SELL	$1.61 - $2.5 $1,938 - $3,010	-1,204 Reduced 0.72%	165,474 $266,000
Q4 2021 Feb 10, 2022	BUY	$2.3 - $4.71 $10,899 - $22,320	4,739 Added 2.93%	166,678 $399,000
Q3 2021 Nov 09, 2021	SELL	$3.36 - $4.79 $17,841 - $25,434	-5,310 Reduced 3.17%	161,939 $744,000
Q2 2021 Aug 11, 2021	BUY	$3.61 - $5.23 $603,768 - $874,712	167,249 New	167,249 $798,000

133K

Ticker ACOR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 24,338,400
Market Cap $6.33M
Description
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.